tDCS (Transcranial Direct Current Stimulation)

Mechanisms and stimulation parameters: 1) Basic mechanism - weak direct current (typically 1-2 mA) delivered via two scalp electrodes (anode = positive, cathode = negative); current flows through brain tissue, modulating resting membrane potential; anodal stimulation depolarizes neurons (excitatory), cathodal hyperpolarizes (inhibitory); 2) Magnitude - typical current density 0.029-0.08 mA/cm² for 1-2 mA over 25-35 cm² electrode; intracerebral electric field <1 V/m (much smaller than TMS); 3) Duration - sessions typically 20-40 minutes; effects outlast session for 30-90 minutes; multiple sessions accumulate effects; 4) Mechanism of plasticity - effects on NMDA receptors, GABA modulation, BDNF release, mitochondrial function changes, glial activation; resembles LTP/LTD; 5) Electrode types - traditional saline-soaked sponges (5x7 cm, 25-35 cm²), high-definition (HD) electrodes (smaller, more focal), gel-based; placement based on 10-20 EEG system or individualized via MRI; 6) Protocols and applications - varied based on goals: 1-2 mA for 20 min, 1-2 sessions/day, 5-10 days; high-definition tDCS (HD-tDCS) more focal; transcranial alternating current stimulation (tACS) - oscillatory; transcranial random noise stimulation (tRNS) - random frequencies; 7) Combined applications - tDCS + cognitive training, tDCS + motor task, tDCS during rehabilitation; effects often greater with combined approach; 8) Safety - very safe in healthy subjects with no reported seizures; mild and tolerable side effects (tingling, itching, mild burning, headache, fatigue, nausea); rare cases of skin burn at electrode site; contraindications - metal in head, pacemaker, severe scalp lesions, history of seizures; 9) Pediatric considerations - increasing use in children; safety established for short courses; longer-term studies needed.

Stroke neurorehabilitation: 1) Stroke motor recovery rationale - similar to TMS, exploits interhemispheric inhibition imbalance; anodal tDCS over ipsilesional M1 to enhance excitability, cathodal tDCS over contralesional M1 to reduce overactivity; 2) Anodal tDCS over ipsilesional M1 - randomized trials demonstrate improvements in upper extremity motor function (Wolf Motor Function Test, Action Research Arm Test, Fugl-Meyer); particularly effective when combined with task-specific motor training, robotic therapy, or constraint-induced movement therapy; subacute and chronic stroke responsive; 3) Cathodal tDCS over contralesional M1 - similar benefits in some studies; combined with motor training; 4) Bihemispheric tDCS - anodal ipsilesional + cathodal contralesional simultaneously; theoretical advantage but mixed evidence; 5) Aphasia rehabilitation - anodal tDCS over Broca area or right inferior frontal gyrus (depending on damage), cathodal over right Broca homologue; benefits in chronic non-fluent aphasia; combined with speech therapy; 6) Hemispatial neglect - cathodal tDCS over contralesional posterior parietal cortex, anodal over ipsilesional; 7) Dysphagia - tDCS over pharyngeal motor cortex with dysphagia therapy; emerging evidence; 8) Attention deficits - prefrontal stimulation; 9) Cognitive function - prefrontal cortex tDCS for working memory, attention, executive function in stroke; 10) Time course and dosing - course typically 5-10 sessions over 1-2 weeks; effects sustained weeks after course; longer/repeated courses; combination with rehabilitation maximizes benefit.

Other applications, comparison with TMS, and future: 1) Chronic pain - anodal M1 tDCS contralateral to pain; fibromyalgia (anodal M1 or DLPFC), neuropathic pain, post-stroke central pain, migraine, complex regional pain syndrome; meta-analyses suggest moderate benefit, requires ongoing treatment; 2) Depression - anodal left dorsolateral prefrontal cortex, cathodal right; evidence mixed but accumulating; FDA approval pending; 5-10 sessions; combined with antidepressants or psychotherapy; 3) Cognitive enhancement - anodal tDCS over prefrontal cortex for working memory, attention, executive function; pilot studies in healthy individuals and disorders (Alzheimer, MCI, ADHD); 4) Multiple sclerosis - anodal M1 for fatigue and motor; emerging evidence; 5) Parkinson disease - anodal M1 for bradykinesia; mixed evidence; 6) Epilepsy - cathodal over seizure focus; emerging research; 7) Schizophrenia - DLPFC for cognitive symptoms, auditory hallucinations targeting temporal cortex; 8) Addiction - DLPFC for craving and impulsivity; smoking, alcohol, food addiction emerging; 9) tDCS vs TMS comparison - tDCS less expensive ($1000-5000 vs $50000+), portable, easier to use, fewer side effects, can be combined more readily with rehabilitation; less focal, less intense, less established efficacy; both have role in different applications; 10) Future developments - high-definition tDCS for focal stimulation, individualized stimulation based on MRI/connectome, home-use devices with telemedicine supervision (already commercialized), combination protocols (tDCS + tACS + behavioral training), wearable continuous tDCS, more clinical applications, improved targeting, integration with rehabilitation systems, regulatory pathway clarification, broader insurance coverage; 11) Home-use considerations - safety, supervision protocols, patient education, technical support, integration with telemedicine, periodic clinical assessment; 12) Research priorities - randomized trials with sham control, individualized parameters, long-term follow-up, biomarker-guided treatment, optimal protocols for specific conditions, mechanistic studies of plasticity, comparative effectiveness with TMS and other rehabilitation.